Company: RGNT
Filing Date: 2025-05-05
Form Type: F-1/A
Source: 0001213900-25-039589
Chunk: 263

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-05
Form: F-1/A
Chunk 263
---
 2024 |     |   | December 31, 
         2023 |
|:------------------------------|:----|:--|-------------:|:----|:--|-------------:|
| Grant liability               |     | $ |            - |     | $ |        2,054 |
| Accrued expenses              |     |   |          697 |     |   |          518 |
| Accrued employee compensation |     |   |            4 |     |   |            3 |
| Other payables                |     |   |            - |     |   |            1 |
| Total                         |     | $ |          701 |     | $ |        2,576 |

<div align='center'>F-14</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 5:- | SHORT-TERM LOANS |

| a. | On August 15, 2023,                                                                          
 the Company obtained a loan at an aggregate amount of $325 from current shareholders and     
 officers of the Company and several new investors. According to the loan agreement, the loan 
 will be repaid within 30 days at the earlier of:                                             |

| 1. | Receipt of a grant                                
 of 300,000 Euro from the Horizon 2020 Program, or |

| 2. | Consummation of the                       
 merger with OceanTech (refer to Note 1b). |

| The proceeds from the loan agreements were allocated                                          
 at the issuance date to the warrants and to the short-term loan. The warrants were measured   
 at fair value and the remaining amount allocated to the short-term loan. The fair value of    
 the warrants at the measurement date was $288. The short-term loan is subsequently measured   
 at its amortized cost. The Company recorded amortization of a discount as an interest expense 
 of $115 and $173 for the short-term loan, within financial expense line in the statements     
 of comprehensive loss for the year ended December 31, 2024 and 2023, respectively.            |

| As result of the cancellation of the Merger Agreement 
 with OceanTech those warrants were cancelled.         |

| In April 2024, the Company received the grant from                                       
 the Horizon 2020 Program in the amount of $320 and repaid the outstanding balance of the 
 loan received in August